Navigation Links
Researchers identify genes associated with lung transplant rejection

Researchers at the San Francisco VA Medical Center (SFVAMC) and the University of California, San Francisco (UCSF) have identified six genes associated with lymphocytic bronchitis, which is thought to lead to obliterative bronchitis (OB), the most common cause of long-term failure of transplanted lungs.

The researchers hope their results will lead to an earlier, more sensitive, and more accurate standard test for chronic lung rejection, as well as greater understanding of the rejection process.

The study is being published in the September 2005 issue of the Journal of Heart and Lung Transplantation, currently available online.

In obliterative bronchitis, scar tissue forms in breathing passages of the transplanted lung, narrowing them and eventually making it impossible for the recipient to breathe. The exact cause is unknown, but it is believed to be related to rejection of the lung by the recipient's body.

"For lung transplant patients, the biggest barrier to long-term survival is control of rejection," says principal investigator George Caughey, MD, head of Pulmonary and Critical Care Medicine at SFVAMC. "If we know rejection is occurring, we can adjust the patient's medication to try and prevent it. But the problem with lung transplants is that it's hard to detect chronic rejection." Currently, he says, OB is best detected through a breathing test--but by the time the disease has a perceptible impact on the patient's ability to breathe, it's often too late to treat effectively.

Caughey and his fellow researchers studied lung biopsy samples from 22 lung transplant patients, with the goal of detecting genes and gene products associated with inflammation and formation of scar tissue in breathing passages. Using a customized version of a conventional laboratory technique, they found that they were able to look at hundreds of gene products simultaneously in lung tissue samples only a few millimeters across. "That was our first ac hievement: being able to accurately measure that many genes in small samples," notes Caughey, who is also a professor of medicine at UCSF. "We succeeded way beyond our expectations."

The researchers then correlated the genetic test results with results from microscopic pathology examinations, tissue cultures, X-rays, CT scans, and breathing tests in each patient. They identified six genes that correlate with lymphocytic bronchitis, potentially opening the way to a genetic test that would identify OB before it manifests. "The beauty of this approach is that it could be applied in a regular laboratory," Caughey says.

However, he cautions, "we need to validate this data in a larger, separate set of patients to prove that these biomarker genes actually work. And we're testing that now." Currently, Caughey's research team is studying biopsy samples from more than 100 UCSF lung transplant patients, who regularly undergo biopsies as part of standard follow-up care.

Another potential benefit of the research, predicts Caughey, will be a better understanding of lung rejection at the genetic level. In turn, he believes, this could lead to the development of medications that directly target genes responsible for the scarring process in the lung, instead of anti-rejection drugs that broadly compromise the immune system, which are the major tools currently available to fight lung rejection.

Co-authors of the study were Xiang Xu, MD, PhD, Jeffrey A. Golden, MD, Gregory Dolganov, PhD, Kirk D. Jones, MD, Samantha Donnelly, PhD, and Timothy Weaver, Bsc, all of UCSF.


'"/>

Source:University of California - San Francisco


Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. Researchers reveal the infectious impact of salmon farms on wild salmon
5. Researchers identify target for cancer drugs
6. Researchers discover molecule that causes secondary stroke
7. Researchers find missing genes of ancient organism
8. Researchers trace evolution to relatively simple genetic changes
9. Researchers add new tool to tumor-treatment arsenal
10. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
11. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):
(Date:3/1/2017)... WA (PRWEB) , ... March 01, 2017 , ... ... research into the physiology of aging into clinical applications, announces the formation of ... proprietary oral-transmucosal dosage form of resveratrol, the drug which has been discussed in ...
(Date:2/28/2017)... Linda, Ca (PRWEB) , ... February 28, 2017 , ... ... molecular interactions. SPR is an optical phenomenon that is sensitive to changes in the ... resonance condition is affected by changes in refractive index occurring up to 300 nm ...
(Date:2/28/2017)... , Feb. 28, 2017  Phosphorus, a ... today the formation of the Phosphorus Scientific Advisory ... experts chosen to advise the company on the ... multi-site research initiatives. Please visit http://phosphorus.com/about-us/ ... initiatives. "We,ve gathered some of the ...
(Date:2/28/2017)... -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing ... diseases, asthma and allergic diseases and cancer, today ... full year ended December 31, 2016 and provided ... clinical highlights. "During 2016, we made ... starting five clinical trials across our XmAb portfolio.  ...
Breaking Biology Technology: